



Investor Update

March 2019

LOOKING AT
MENTAL HEALTH,
OBJECTIVELY

Forward Looking Statements

The purpose of the presentation is to provide an update of the business of Medibio Limited (ASX:MEB) (OTCQB: MDBIF). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification.

Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Medibio Limited and should not be relied upon as an independent source of information. Please contact Medibio Limited and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified.

None of Medibio Limited, or any of its affiliates or associated companies (or any of their officers, employees, contractors or agents (the Relevant Persons)) makes any representation or warranty as to the accuracy, completeness or reliability of the information, or the likelihood of fulfillment of any forward looking statement or any outcomes expressed or implied in any forward looking statements.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Medibio Limited's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks.

Because actual results could differ materially to assumptions made and Medibio Limited's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. Except as required by applicable law or the ASX listing rules, the Relevant Persons disclaim any obligation or undertaking to publicly update any statements in this presentation, whether as a result of new information or future events.

This presentation should not be relied on as a recommendation or forecast by Medibio Limited. Nothing in this presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.



The mental health technology company leveraging objective digital biomarkers for products and services that assist in screening, diagnosing, monitoring, and managing of depression and other mental health conditions.

Corporate Structure

CAPITAL STRUCTURE (ASX:MEB) (OTCQB:MDBIF)

Market Cap	AU\$4.05M
Share price <i>as of 15 March 2019</i>	AU\$0.016
Shares on Issue	249M
Cash¹	AU\$2.15M

1. Cash balance as of 31 December 2018

Shortfall

Shares Available	156.5M
Shares on Issue*	405.5M

* Assumes full uptake on shortfall

RE-STARTUP STRATEGY

Medibio's RE-STARTUP is progressing on plan:

- ✓ Restructured Board and Key Management
- ✓ New Cost Controls to Reduce Cash Burn
- ✓ Strengthened Regulatory Path
- ✓ Prioritised Business Segments
- ✓ Commercial launch of ilumen™
- ✓ Enhanced Communication with Stakeholders



RESTRUCTURED BOARD AND KEY MANAGEMENT

22 February 2019

- Andrew Maxwell resigned as Non-Executive Director
- Melanie Leydin appointed to Australian Director position
- Board elected David B. Kaysen to the position of Chairman in addition to his current Managing Director & CEO positions
- Board appointed Peter Carlisle as Lead Independent Director

4 February 2019

Peggy Morgan appointed as Corporate Controller

1 January 2019

Brian Mower, as part of cost savings, ceased as CFO

Board of Directors



DAVID B. KAYSEN
Chair, Managing Director & CEO



PETER CARLISLE
Lead Independent Director
Managing Director, Olympics &
Action Sports, Octagon Worldwide



DR FRANKLYN G PRENDERGAST
PhD MD, Non Executive Board Member
Former member board of Trustee and Board of
Governors Mayo Clinic and board member Eli Lilly



PATRICK KENNEDY
Non Executive Director
Former US Congressman
Founder, Kennedy Forum



MICHAEL PHELPS
Non Executive Director
Mental Health Advocate



CLAUDE SOLITARIO
Non Executive Director
Founding Shareholder



MELANIE LEYDIN
Director & Joint Company Secretary
B. Bus, CA



MATHEW WATKINS
Joint Company Secretary
B. Bus, CA

Executive Team



DAVID B. KAYSEN
Chair, Managing Director & CEO



PEGGY MORGAN
Corporate Controller



ARCHIE DEFILLO
Chief Medical Officer



JEREMY SCHROETTER
Chief Technology Officer



JENNIFER SOLITARIO
Senior Vice President Corporate Health



LINDSEY HAGAN
Vice President Strategy & Business
Development


COST CONTROLS TO REDUCE CASH BURN

Focus on reducing cash burn to achieve **target of monthly average spend of less than \$500K**

- Significant reduction in force, U.S. office
- Cash compensation eliminated for NED's, effective 1 January 2019
- All line item spending scrutinised & reduced
- Reduction in spending in Australian office
- Outsourcing of psychology services in support of ilumen™ corporate health product
- Downsized Perth premise and working to sublet or reassign the current lease on the property




QUARTERLY CASH BURN



On track to achieve monthly burn rate target of approximately \$500K

BUSINESS Objectives – Regulated & Unregulated Product Pipeline



PRODUCT OVERVIEW – U.S. Regulated Pathway

FDA 510(k)



- ▶ Mental Health Regulated Product – FDA Clearance Process in the U.S.
- ▶ Expect 510(k) decision in Q2 CY2019
 - Product focused on providing clinicians new data points
 - Gather data on Heart Rate Variability (HRV)
 - Gather additional data from in-patient sleep studies
- ▶ Improve Clinician assessment of patient's mental health
- ▶ Will explore license agreements and other forms of commercialisation

PRODUCT OVERVIEW – U.S. Regulated Pathway

FDA De Novo



- ▶ Mental Health Regulated Product – FDA Clearance Process in the U.S.
- ▶ Improve Clinician assessment of patient's mental health
- ▶ Continue to prepare response to FDA De Novo Application
 - Company has begun positive and open dialogue with FDA
 - The original submission has shortcomings
 - FDA is helping to guide us through the process and has provided excellent directional feedback about our technology
 - 29 April 2019 MEB to respond to FDA
 - Company is encouraged by dialogue with FDA, with end point anticipated in late CY2020, as previously disclosed

PRODUCT OVERVIEW – Corporate Health

Australia

ilumen™ in Corporate Health Market



Pilot programs marketed to large corporations with goal to scale up partnerships

- One pilot completed with high participation
- AIAA pilot commences in March 2019
- In discussion with large multinational company with potential for several pilot programs

Receiving unsolicited enquiries from large corporations

- Being selective due to constraints with funding and people, while focusing on large scale commercialization

App based system provides feedback to individual

- De-identified aggregate feedback to Corporate partner



Looking to Expand...

- **Focus on Better Use of Biometrics**
- **Continue to Improve Biometric Algorithm**
(based on wearable data collected)



RECENT CAPITAL RAISING

- ▶ Completed Convertible Note issue in January 2019, raising approximately \$2.75 million over two tranches
- ▶ Completed a Non-Renounceable Entitlement Offer to existing shareholders raising \$923,465
- ▶ The Company is seeking to fulfil the shortfall on the Entitlement issues, which will provide a longer-term runway
- ▶ The combined capital raisings, based on strong participation on the shortfall, is expected to provide 12+ months of cash with cost reductions in place



THANK YOU

8696 Eagle Creek Circle
Savage, MN 55378 USA

medibio.com.au

LOOKING AT
MENTAL HEALTH,
OBJECTIVELY